Journal
JOURNAL OF HEMATOLOGY & ONCOLOGY
Volume 13, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s13045-020-00962-7
Keywords
B cell maturation antigen; BCMA; Belantamab mafodotin; CAR-T; Antibody-drug conjugate; Bispecific T cell engager
Categories
Ask authors/readers for more resources
B cell maturation antigen (BCMA) is a novel treatment target for multiple myeloma (MM) due to its highly selective expression in malignant plasma cells (PCs). Multiple BCMA-targeted therapeutics, including antibody-drug conjugates (ADC), chimeric antigen receptor (CAR)-T cells, and bispecific T cell engagers (BiTE), have achieved remarkable clinical response in patients with relapsed and refractory MM. Belantamab mafodotin-blmf (GSK2857916), a BCMA-targeted ADC, has just been approved for highly refractory MM. In this article, we summarized the molecular and physiological properties of BCMA as well as BCMA-targeted immunotherapeutic agents in different stages of clinical development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available